# US 2023/0390358 A1 · Method for alleviating depression using tnfaip3-interacting protein (tnip) 1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0390358 A1
- Document ID: US20230390358A1
- Status: Published application
- Kind: A1
- Application number: 18/112,554
- Filed: 2023-02-22
- Published: 2023-12-07
- Earliest claimed: 2022-06-02
- Assignees: Kaohsiung Chang Gung Memorial Hospital
- Applicants: Kaohsiung Chang Gung Memorial Hospital
- Inventors: Yi-Yung Hung; Hong-Yo Kang; Ching-Yi Tsai; Ya-Ling Huang
- Web page: https://patentgrep.com/patent/US20230390358A1

## CPC

- A61K 38/1709: {from mammals}
- A61K 38/191: {Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta}
- A61P 25/24: Antidepressants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein is a method for alleviating depression, which includes administering to a subject in need thereof a composition containing TNFAIP3-interacting protein (TNIP) 1. The composition is administered to the CA3 region of the subject's hippocampus.

## Claims

### Claim 1

A method for alleviating depression, comprising administering to a subject in need thereof a composition containing TNFAIP3-interacting protein (TNIP) 1,
wherein the composition is administered to the CA3 region of the subject's hippocampus.

### Claim 2 (depends on 1)

The method as claimed in claim 1, wherein the composition is formulated as a pharmaceutical composition.

### Claim 3 (depends on 2)

The method as claimed in claim 2, wherein the pharmaceutical composition is in a parenteral dosage form.

### Claim 4 (depends on 3)

The method as claimed in claim 3, wherein the pharmaceutical composition is in a dosage form for intracranial injection.
